SCHEDULE: Vanguard Group Adjusts Avita Medical Stake Below 5%

The Vanguard Group filed an amended Schedule 13G, reporting a 4.73% beneficial ownership in Avita Medical Inc. common stock as of December 31, 2025, following an internal realignment.

Summary

• The Vanguard Group reported beneficial ownership of 1,444,579 shares of Avita Medical Inc. common stock.
• This represents 4.73% of the class of securities.
• The filing indicates shared voting power over 190,616 shares and shared dispositive power over 1,444,579 shares.
• The Vanguard Group, Inc. underwent an internal realignment on January 12, 2026, ceasing portfolio management services and proxy voting administration.
• Certain subsidiaries or business divisions of Vanguard Group, Inc. are expected to report beneficial ownership separately going forward.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Avita Medical Inc.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing. While the ownership is below 5%, it confirms a continued significant passive stake by a major institutional investor, offset by the complexity introduced by Vanguard's internal realignment for future tracking.

Positives

• The Vanguard Group, a major institutional investor, continues to hold a significant stake in Avita Medical Inc., indicating continued confidence in the company's long-term prospects.
• The holding is for ordinary course of business, not for control, suggesting a passive investment strategy.

Negatives

• The internal realignment at Vanguard means future reporting will be disaggregated, potentially making it harder to track the aggregate Vanguard position in Avita Medical Inc.

Risks

• The internal realignment at The Vanguard Group could lead to a more fragmented view of their overall investment strategy in Avita Medical Inc. as subsidiaries report separately.

Future Outlook

The Vanguard Group, Inc. anticipates that certain subsidiaries or business divisions will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. following an internal realignment effective January 12, 2026. These subsidiaries and/or business divisions will pursue the same investment strategies as previously pursued by The Vanguard Group, Inc.

Management Comments

• On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. As of that date, The Vanguard Group, Inc. no longer performs portfolio management services or administers proxy voting.
• The Vanguard Group, Inc. anticipates that certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that currently have, or are deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release.
• These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment.
• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine disclosures by passive institutional investors. The internal realignment at The Vanguard Group reflects a broader trend among large asset managers to optimize operational structures and potentially streamline reporting responsibilities across their diverse investment vehicles. This disaggregation of reporting, while compliant, may require investors to track multiple filings to ascertain the full extent of Vanguard's collective holdings in Avita Medical Inc.

Comparison to Industry Standards

• This filing is a standard Schedule 13G, indicating passive investment intent, which is typical for large asset managers like The Vanguard Group. Compared to activist investors who might file a Schedule 13D, Vanguard's filing confirms its role as a long-term, non-interfering shareholder. No specific comparable companies or projects are mentioned in the filing to assess performance against industry benchmarks.

Stakeholder Impact

• Shareholders: Provides transparency on a significant institutional holding, confirming a passive investment stance. Future disaggregated reporting from Vanguard's subsidiaries might require more effort to track total Vanguard exposure.
• Management: Confirms a large, passive institutional investor, which typically implies stability and less pressure for immediate strategic changes.

Next Steps

• Certain subsidiaries or business divisions of The Vanguard Group, Inc. are expected to report beneficial ownership separately from The Vanguard Group, Inc. in future filings.

Key Dates

Recommendation

This Schedule 13G filing is a routine disclosure of passive beneficial ownership by a large institutional investor. It does not contain new financial performance data, strategic updates, or material events that would warrant a change in investment recommendation. The continued significant, albeit passive, stake by The Vanguard Group suggests a long-term 'hold' perspective for existing investors, while new investors would need to consider broader company fundamentals beyond this ownership report.

Keywords

Avita Medical Inc, Vanguard Group, Schedule 13G, Common Stock, Beneficial Ownership, Institutional Investor, SEC Filing, Investment Adviser